News

Several clinical trials are examining the role of stem cells, inflammation, and other pathways in ALS.

Hendrix spoke to the challenges he and colleagues come across, as well as his hope for the promising future.

A nationwide, case-controlled study found the use of benzodiazepines and related z-drugs increased the risk of patients developing Alzheimer disease.

The director of the Partners Pediatric Multiple Sclerosis Center at Massachusetts General Hospital spoke about the current landscape of MS treatment.

Robbins discusses the exciting future of true designer drugs in the works for migraine prevention as well as the challenges that remain in the space.

Seasickness can be difficult to manage once symptoms begin. However, there are some physiological characteristics to help patients manage symptoms.

Selkoe spoke to a number of topics in the Alzheimer space, including the challenges in the field and his excitement for the future.

For those at-risk for Parkinson disease, reducing systemic inflammation could decrease the incidence of the movement disorder.

Lutz Frölich, MD, PhD, discussed the imperativeness of collaboration between stakeholders—clinicians, pharmaceutical companies, researchers—in developing therapies for Alzheimer disease.

The neurosurgeon from Sunnybrook Health Sciences Centre spoke about his excitement about where the medical community is at, at this point, in the understanding of Alzheimer disease.

This is the first study to utilize artificial intelligence for detecting a wide range of acute neurologic events, demonstrating a direct clinical application.

The nonselective ß-blocker proved efficacious in comparison with placebo in a pilot trial.

The investigational drug is in development for treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping.

Livingston spoke to a number of topics in the dementia space, including the challenges clinicians face and her hope for the future.

Darin Okuda, MD, provides insight into the nuances that come with the treatment of MS with disease-modifying therapies.

The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health talked about the biggest challenges facing medicine in treating and understanding Alzheimer disease.

Could GlaxoSmithKline and 23andMe use genetic data to create landscape-altering therapies for hard-to-treat conditions?

DREAMS-START demonstrates that a manual-based psychological treatment for sleep disorders in dementia is feasible and acceptable.

Can better collaboration between industry and clinicians solve the challenges that plague the Alzheimer community?

Nabilone significantly improved agitation, neuropsychiatric symptoms, cognition and nutrition in patients with moderate-to-severe Alzheimer disease.

Neurology Times invited David E. Olson, PhD to discuss a new study that sheds light on the role of psychedelics in promoting neuritogenesis, spinogenesis, and synaptogenesis.

The founder and CEO of T3D Therapeutics, Inc., spoke about T3D’s desire to go against the grain and trend in the therapeutic development for mild to moderate Alzheimer disease.

The findings suggest that intensive lowering of blood pressure may reduce the risk of mild cognitive impairment and the combined risk of mild cognitive impairment and dementia, but not dementia alone.

The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health discussed his thoughts about patients with mild dementia and prodromal Alzheimer disease.

The increased risk of hemorrhage was not revealed in 5-mg and 10-mg doses, implying a dose-dependent effect for rivaroxaban.

Paramedics were called to a campus party after a 911 call was placed with a report that a 19-year-old male suddenly “passed out.”

Data back a 4-fold higher dose of crenezumab in the CREAD 1 and CREAD 2 trials than used in phase II.

Midazolam is expected to receive a decision from the FDA in early 2019. If approved, it would become the first new medication for this indication in more than 15 years.